Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Pipeline Snapshot as of July 28, 2021

  • Discovery Projects
  • Phase 1
    29
  • Phase 2
    40
  • Phase 3
    23
  • Registration
    8
  • Total100
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
PF-06482077
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (adult) (E.U.) Registration New Molecular Entity Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
Go to clinical trial
COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S.; E.U.) (12 years of age and older) Registration New Molecular Entity Vaccine
TicoVac
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Tick-borne encephalitis (TBE) (U.S.) Registration New Molecular Entity Vaccine
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary Clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (pediatric) (BREAKTHROUGH, FAST TRACK) Phase 3 Product Enhancement Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY Meningococcal Infections (adolescent and young adults) Phase 3 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Respiratory Syncytial Virus Infection (maternal) (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive Group B Streptococcus Infection (maternal) (FAST TRACK) Phase 2 New Molecular Entity Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (infants and children) Phase 2 New Molecular Entity Vaccine
PF-07307405
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Lyme disease (FAST TRACK) Phase 2 New Molecular Entity Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (maternal) Phase 2 Product Enhancement Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (children 2 to 11 years of age) Phase 2 Product Enhancement Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (infants 6 months to <24 months) Phase 2 Product Enhancement Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Serogroups ABCWY Meningococcal Infections (infants)
Project advanced
Phase 2 Product Enhancement Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Respiratory Syncytial Virus Infection (adult)
Project advanced
Phase 2 Product Enhancement Vaccine
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (E.U.) Registration Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 kinase inhibitor
Go to clinical trial
ER+/HER2+ Metastatic Breast Cancer(PATINA) Phase 3 Product Enhancement Small Molecule